BRAIN-DERIVED NEUROTROPHIC FACTOR (BI)NF)

Authored by

mohammad looti

November 5, 2025

BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF)

Primary Disciplinary Field(s): Neuroscience, Molecular Biology, Psychiatry

1. Core Definition

Brain-Derived Neurotrophic Factor (BDNF) is a crucial member of the neurotrophin family of growth factors, a group of proteins vital for the survival, differentiation, and maintenance of neurons in both the central nervous system (CNS) and the peripheral nervous system (PNS). BDNF is widely distributed throughout the brain, although it is particularly highly expressed in the **hippocampus**, cortex, and cerebellum, regions integral to memory, learning, and motor control. Its primary role is fundamentally linked to supporting neuronal health and promoting functional adaptability, making it essential for processes underlying cognitive function and emotional regulation. Unlike other neurotrophins, BDNF possesses a potent capacity to promote the outgrowth and complexity of dendrites and axons, thereby strengthening neural circuits and facilitating signal transmission.

Synthesized as a precursor protein, proBDNF, it undergoes complex cleavage to become mature BDNF, which is the biologically active form. The balance between proBDNF and mature BDNF is critical, as proBDNF can actually induce apoptosis (programmed cell death) and long-term depression (LTD), suggesting that the ratio of these two forms plays a regulatory role in synaptic plasticity. The gene encoding BDNF is highly conserved across species, underscoring its evolutionary significance in complex nervous systems. The integrity of BDNF signaling pathways is indispensable for healthy brain function, and any significant perturbations in its expression or activity are often associated with profound physiological and psychological consequences, including the psychiatric disorders noted in early research.

The definition extends beyond mere survival promotion; BDNF acts as a sophisticated signaling molecule, mediating communication between neurons. It functions as a powerful regulator of gene expression within target neurons, influencing the production of various proteins necessary for long-term structural and functional changes. Its influence spans from early developmental stages, guiding axon pathfinding and target innervation, through adulthood, where it is a primary driver of experience-dependent **synaptic plasticity**. Therefore, BDNF is often viewed as a key molecular bridge connecting environmental stimuli, cognitive activity, and structural changes within the brain.

2. Etymology and Historical Development

The conceptual framework for neurotrophins began with the groundbreaking work of Rita Levi-Montalcini and Stanley Cohen on Nerve Growth Factor (NGF) in the 1950s, which earned them the Nobel Prize. NGF demonstrated that target tissues release soluble factors necessary for the survival of innervating neurons. BDNF was subsequently discovered in the 1980s by Yves-Alain Barde and colleagues, who were searching for additional factors with similar functions that were

specifically abundant in the brain tissue, hence its name, Brain-Derived Neurotrophic Factor. This discovery validated the hypothesis that a family of neurotrophic factors existed, each potentially serving distinct populations of neurons within the CNS.

Initial studies focused on the potent survival effects of BDNF, particularly its ability to rescue damaged or threatened neurons, establishing its fundamental importance in neuroprotection. However, the subsequent decade saw a rapid expansion of research into its role in functional plasticity. Researchers began to understand that BDNF was not simply a survival factor but an active participant in the dynamic processes of learning and memory formation. Experimental models demonstrated that exogenous BDNF application could enhance long-term potentiation (LTP), the cellular mechanism thought to underlie learning, propelling BDNF into the forefront of research concerning cognitive enhancement and disorder pathophysiology.

A significant milestone in BDNF research involved the identification of its primary high-affinity receptor, the tropomyosin receptor kinase B (**TrkB**). This discovery provided the necessary molecular mechanism to understand how BDNF exerted its diverse effects, detailing the signaling cascades initiated upon binding. The historical trajectory of BDNF research moved from a focus on basic neurobiology to complex clinical applications, particularly after its consistent linkage to major depressive disorder and other psychiatric conditions, thus transforming it from an obscure growth factor into a major therapeutic target.

3. Molecular Structure and Receptor Signaling

BDNF is translated from the *BDNF* gene, which is highly complex, featuring multiple promoters that allow for diverse transcriptional regulation, leading to the expression of various BDNF mRNA transcripts. This complexity in transcription allows different brain regions or cell types to regulate BDNF expression in response to specific activity patterns or environmental cues. The protein is initially synthesized as proBDNF, which is trafficked through the secretory pathway. Maturation involves enzymatic cleavage, typically by proteases such as furin within the cell or plasmin outside the cell, which yields the mature, biologically active BDNF dimer.

Mature BDNF functions primarily by binding to the TrkB receptor, a receptor tyrosine kinase. The binding of BDNF causes the dimerization and subsequent autophosphorylation of TrkB receptors on the neuronal surface. This phosphorylation event activates multiple intracellular signaling cascades, which are critical for mediating BDNF's long-term effects. The three main signaling pathways activated downstream of TrkB are the **Mitogen-Activated Protein Kinase (MAPK)/ERK pathway**, the Phosphatidylinositol 3-Kinase (PI3K)/Akt pathway, and the Phospholipase C gamma (PLCγ) pathway. The MAPK pathway is crucial for transcriptional regulation and synaptic plasticity, while the PI3K/Akt pathway is essential for neuronal survival by inhibiting pro-apoptotic signals. The PLCγ pathway mediates the mobilization of intracellular calcium, which affects neuronal

excitability and synaptic release.

The proBDNF form, conversely, binds preferentially to the p75 neurotrophin receptor (**p75NTR**), which often signals for opposing functions, including neuronal apoptosis and synaptic pruning. This dual signaling system--TrkB promoting survival and plasticity, and p75NTR often promoting death or depression--highlights the delicate regulatory mechanism governing neuronal fate and function. The availability of proteases to convert proBDNF to mature BDNF thus acts as a crucial switch, determining whether the neurotrophin promotes growth or triggers destructive processes.

4. Functional Roles in the Central Nervous System

The functional significance of BDNF in the CNS revolves around three major pillars: promoting neuronal survival, driving **neurogenesis**, and regulating synaptic plasticity. In terms of survival, BDNF acts as a potent anti-apoptotic factor, particularly important for medium spiny neurons in the striatum and certain sensory neurons. During development, it ensures that only appropriately wired and healthy neurons survive the period of natural cell death, thereby refining neural circuits. In the adult brain, this protective function is paramount in mitigating insults such as ischemia or oxidative stress.

BDNF is perhaps most famously recognized for its role in synaptic plasticity, the capacity of synapses to strengthen or weaken over time in response to activity. It is crucial for the induction and maintenance of long-term potentiation (LTP), the lasting increase in synaptic efficacy that serves as the molecular substrate for memory storage. By promoting the delivery and insertion of AMPA receptors into the postsynaptic membrane, BDNF enhances excitability and facilitates communication between neurons. Conversely, dysregulated BDNF signaling can contribute to long-term depression (LTD), suggesting that the timing and location of BDNF release are tightly controlled and critical for governing the direction of synaptic change.

Furthermore, BDNF is a key mediator of adult neurogenesis, particularly within the subgranular zone of the hippocampal dentate gyrus. It promotes the proliferation, differentiation, and survival of newborn neurons. This process is essential for learning, spatial memory, and affective regulation. Environmental factors known to increase neurogenesis, such as physical exercise and enriched environments, typically operate by increasing BDNF expression in the hippocampus. This functional link highlights how environmental input translates into structural changes in the adult brain, facilitating adaptation and resilience.

5. Association with Psychiatric and Neurological Disorders

A vast body of clinical and preclinical evidence links dysregulation of BDNF signaling to numerous psychiatric and neurological disorders. A consistent finding in post-mortem studies and peripheral measures (e.g., serum BDNF levels) of patients suffering from **Major Depressive Disorder (MDD)**

is significantly reduced BDNF levels, particularly in the hippocampus and prefrontal cortex. The "neurotrophic hypothesis of depression" posits that stress leads to a decrease in BDNF, causing atrophy and loss of function in vulnerable brain regions, which is reversed by successful antidepressant treatment, which often correlates with an increase in BDNF expression.

Beyond depression, BDNF deficits are implicated in the pathophysiology of schizophrenia, where altered BDNF levels and polymorphisms in the *BDNF* gene are frequently observed. These alterations may contribute to the cognitive deficits, structural abnormalities (such as reduced cortical thickness), and abnormal synaptic connectivity characteristic of the disorder. Similarly, anxiety disorders and Post-Traumatic Stress Disorder (PTSD) show complex, sometimes contradictory, links to BDNF, often depending on the specific brain region and whether proBDNF or mature BDNF is measured, but generally pointing toward a failure in the homeostatic regulation of neural plasticity.

In the realm of neurodegenerative diseases, BDNF acts as a key protective factor. Decreased BDNF signaling is observed early in the progression of Alzheimer's disease (AD) and Parkinson's disease (PD). In AD, reduced BDNF contributes to neuronal vulnerability to amyloid-beta toxicity and tau pathology. For PD, BDNF is critical for the survival of dopaminergic neurons in the substantia nigra. Therefore, BDNF depletion is not merely a consequence of neuronal death but likely an active contributor to the progressive neurodegeneration observed in these chronic conditions, making replacement or enhancement strategies highly attractive therapeutic avenues.

6. Regulation and Modulating Factors

The expression and activity of BDNF are tightly regulated by a wide array of factors, including genetic variation, neuronal activity, and environmental influences. One of the most studied genetic factors is the **Val66Met polymorphism** (rs6265). This single nucleotide change replaces the amino acid valine (Val) with methionine (Met) at codon 66 of the BDNF pro-protein. Individuals carrying the Met allele exhibit impaired intracellular trafficking and secretion of BDNF, leading to lower activity-dependent release of the factor. This polymorphism has been associated with increased susceptibility to anxiety, depression, and impaired episodic memory, providing a direct molecular link between genetics and psychological vulnerability.

Neuronal activity is a potent regulator; intense synaptic activity, such as that associated with active learning or environmental enrichment, rapidly increases BDNF synthesis and release. Conversely, chronic stress, through the action of glucocorticoids (stress hormones), generally suppresses BDNF expression, particularly in the hippocampus, contributing to dendritic atrophy and cognitive impairment. This stress-induced reduction underscores how environmental adversity can directly compromise the brain's capacity for plasticity and repair.

Lifestyle factors provide accessible means of modulating BDNF levels. Physical exercise,

particularly aerobic activity, is consistently shown across numerous studies to elevate BDNF expression in both humans and animal models, correlating strongly with improved mood and cognitive function. Dietary interventions, such as calorie restriction and the consumption of omega-3 fatty acids, are also reported to positively influence BDNF signaling. These regulatory mechanisms highlight that BDNF serves as a crucial molecular interface, translating environmental and behavioral inputs into physiological changes within the nervous system.

7. Therapeutic Potential and Future Directions

Given its pivotal role in neuroprotection and plasticity, BDNF signaling represents a prime therapeutic target for a multitude of CNS disorders. The direct use of recombinant BDNF protein as a drug, however, faces significant challenges, primarily due to the molecule's inability to cross the **blood-brain barrier (BBB)** when administered peripherally, and its short half-life. Invasive delivery methods, such as direct infusion into the brain, carry substantial risks, limiting their clinical applicability.

Current research is focused on developing novel strategies to overcome these limitations. One approach involves the creation of small-molecule BDNF mimetics or agonists that can readily cross the BBB and selectively activate the TrkB receptor, offering a non-invasive way to enhance endogenous BDNF signaling. Another strategy involves using gene therapy techniques to introduce the BDNF gene directly into specific brain regions, providing sustained local production of the protein. Furthermore, understanding the mechanisms by which non-pharmacological interventions, such as electroconvulsive therapy (ECT) or transcranial magnetic stimulation (TMS), exert their antidepressant effects often reveals an upregulation of BDNF, leading to the investigation of targeted neuromodulation aimed at increasing endogenous BDNF release.

The future of BDNF therapeutics also involves refining our understanding of the proBDNF/mature BDNF ratio. Developing compounds that selectively enhance the conversion of proBDNF to mature BDNF, or block the deleterious signaling of proBDNF through p75NTR, offers a more nuanced approach than simply increasing total BDNF expression. Ultimately, harnessing the protective and regenerative power of BDNF holds immense promise for treating chronic neurological and psychiatric illnesses resistant to current therapeutic modalities.

Further Reading

Brain-derived neurotrophic factor (BDNF) - Wikipedia
Tropomyosin receptor kinase B (TrkB) - Wikipedia
Synaptic Plasticity - Wikipedia
Neurogenesis - Wikipedia
Val66Met polymorphism - Wikipedia